RxDoctor Payments Data

Regine Pappas, MD

Ophthalmology · Melbourne, FLNPI 1215921275

Payments from drug & device makers

$48,288in general payments, 2019–2025

Across 458 payments — averaging $105.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$16K
  • AbbVie$11K
  • Alcon$7K
  • Nova Eye, Inc.$6K
  • Eyepoint US, Inc.$1K
  • Glaukos Corporation$1K
  • plus $6K from 25 others

What the payments were for

  • Consulting fees$13,93829%
  • Speaking & faculty fees$15,45732%
  • Travel & lodging$2,5085%
  • Food & beverage$16,34034%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,288 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$414,758
Medicare patients
652
Services billed
3,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost395$203,714
RestasisCyclosporine108$128,518
XiidraLifitegrast27$50,410
RocklatanNetarsudil Mesylat/Latanoprost90$47,084
CombiganBrimonidine Tartrate/Timolol120$41,896
VevyeCyclosporine42$37,710
Travoprost199$34,137
VyzultaLatanoprostene Bunod65$33,685
IlevroNepafenac92$33,682
MieboPerfluorohexyloctane/Pf34$29,621
RhopressaNetarsudil Mesylate61$27,786
Brinzolamide106$23,807
Cyclosporine33$21,104
Alphagan PBrimonidine Tartrate56$19,470
SimbrinzaBrinzolamide/Brimonidine Tart83$18,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$11,081$393,598679 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$558$113,717126 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$16,122$74,870151 claims
Harrow Eye, LLCVevye$183$37,71042 claims
NovartisIlevro$318$33,68292 claims
AlconSimbrinza$6,868$18,55683 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$610$18,42370 claims
Akorn, Inc.Betimol$14$1,74311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →